

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

We claim:

1. (ORIGINAL) A method for inhibiting rejection in a transplant recipient comprising administering to the recipient's donor, prior to transplantation, an effective amount of a VEGF antagonist.
2. (ORIGINAL) The method of Claim 1, further comprising administering a VEGF antagonist to the transplant recipient.
3. (CURRENTLY AMENDED) The method of Claim 1, wherein said ~~transplantation-graft~~ is an allograft.
4. (ORIGINAL) The method of Claim 3, wherein said allograft is selected from the group consisting of kidney, liver, lung, heart-lung, pancreas, bowel and heart.
5. (ORIGINAL) The method of Claim 4, wherein said allograft is a kidney.
6. (CURRENTLY AMENDED) The method of ~~Claim 1~~~~Claims 1 or 2~~, further comprising administering to said donor an effective amount of an immunosuppressive agent and/or a chemokine antagonist.
7. (ORIGINAL) The method of Claim 6, wherein said immunosuppressive agent is one or more agents selected from the group consisting of calcineurin inhibitors, glucocorticoids, nucleic acid synthesis inhibitors and antibodies which bind to lymphocytes.
8. (CANCEL)
9. (CURRENTLY AMENDED) The method of ~~Claim 7~~~~Claim 8~~, wherein said immunosuppressive agent is a calcineurin inhibitor selected from the group consisting of cyclosporin A and FK-506.
10. (CANCEL)

11. (CURRENTLY AMENDED) The method of Claim 7, wherein said immunosuppressive agent is a glucocorticoid selected from the group consisting of prednisone and methylprednisolone.
12. (CANCEL)
13. (CURRENTLY AMENDED) The method of Claim 6-Claim 7, wherein the immunosuppressive agent is selected from the group consisting of mycophenolate mofetil (MMF), and mycophenolate sodium .
14. (CANCEL)
15. (CURRENTLY AMENDED) The method of Claim 1-Claims 1 or 2, wherein the VEGF antagonist is an antibody, monoclonal antibody, or humanized monoclonal antibody.
16. (CANCEL)
17. (CURRENTLY AMENDED) The method of Claim 15-Claim 16, wherein the antibody is Bevacizumab or humanized rat anti-mouse 2G11.
18. (CANCEL)
19. (CANCEL)
20. (CANCEL)
21. (CANCEL)
22. (CANCEL)
23. (CANCEL)
24. (CANCEL)
25. (CANCEL)
26. (CANCEL)
27. (CANCEL)
28. (CANCEL)
29. (CANCEL)
30. (CURRENTLY AMENDED) The method of Claim 2-Claim 18, wherein the VEGF antagonist is an antibody.

31. (ORIGINAL) The method of Claim 30, wherein the antibody is a humanized monoclonal antibody.
32. (CURRENTLY AMENDED) The method of Claim 31, wherein the antibody is Bevacizumab or humanized rat anti-mouse 2G11.
33. (CANCEL)
34. (CURRENTLY AMENDED) The method of claim 1 ~~or 2~~, wherein the VEGF antagonist is one or more agents selected from the group consisting of a small molecule, a peptide, an aptamer, a siRNA, or a ribozyme.
35. (ORIGINAL) The method of claim 34, wherein the small molecule is PTK787.
36. (ORIGINAL) The method of claim 34, wherein the small molecule is selected from the group consisting of SU-6668, SU-5416, rapamycin, or ZK222584.
37. (ORIGINAL) The method of claim 1, wherein the transplant recipient's donor is a marginal donor.
38. (NEW) The method of Claim 2 further comprising administering an effective amount of an immunosuppressive agent and/or chemokine antagonist.